CD38 autoimmunity: Recent advances and relevance to human diabetes

Journal of Endocrinological Investigation

Volumn 27, Issue 7, 2004, Pages 695-707

  Antonelli, A ^a   Ferrannini, E ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Autoimmunity; CD38; Diabetes; Graves' disease; Huma beta cells; Insulin secretion; Intracellular calcium; Thyroiditis

Indexed keywords

AUTOANTIBODY; CALCIUM ION; CD38 ANTIGEN; CYCLIC ADENOSINE DIPHOSPHATE RIBOSE; GLUCOSE; GLUTAMATE DECARBOXYLASE; INSULIN; NICOTINAMIDE ADENINE DINUCLEOTIDE; NICOTINIC ACID ADENINE DINUCLEOTIDE PHOSPHATE;

ACCURACY; ADULT; AGE; ANTIBODY DETECTION; ANTIGEN EXPRESSION; ASIAN; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CALCIUM CELL LEVEL; CALCIUM TRANSPORT; CATALYSIS; CAUCASIAN; CELL CULTURE; CELL FUNCTION; CELL TYPE; DIABETES MELLITUS; DISEASE COURSE; DISEASE DURATION; GENE MUTATION; HUMAN; IN VIVO STUDY; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; LYMPHOID CELL LINE; MISSENSE MUTATION; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PANCREAS ISLET; PHENOTYPE; REVIEW; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE;

EID: 5444253820     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03347507     Document Type: Review

References (90)

1. Reinherz EL, Kung PC, Goldstein G, Levey RH, Schlossman SF. Discrete stages of human intrathymic differentiation: analysis of normal thymocytes and leukemic lymphoblasts of T-cell lineage. Proc Natl Acad Sci USA 1980, 77: 1588-92.
2. Malavasi F, Caligaris-Cappio F, Milanese C, Dellabona P, Richiardi P, Carbonara AO. Characterization of a murine monoclonal antibody specific for human early lymphohemopoietic cells. Hum Immunol 1984, 9: 9-20.
3. Alessio M, Roggero S, Funaro A, et al. CD38 molecule: structural and biochemical analysis on human T lymphocytes, thymocytes, and plasma cells. J Immunol 1990, 145: 878-84.
4. States DJ, Walseth TF, Lee HC. Similarities in amino acid sequences of Aplysia ADP-ribosyl cyclase and human lymphocyte antigen CD38. Trends Biochem Sci 1992, 17: 495.
5. Funaro A, De Monte LB, Dianzani U, Forni M, Malavasi F. Human CD38 is associated to distinct molecules which mediate transmembrane signaling in different lineages. Eur J Immunol 1993, 23: 2407-11.
6. Grakoui A, Bromley SK, Sumen C, et al. The immunological synapse: a molecular machine controlling T cell activation. Science 1999, 285: 221-7.
7. Dustin ML, Shaw AS. Costimulation: building an immunological synapse. Science 1999, 283: 649-50.
8. Deaglio S, Morra M, Mallone R, et al. Human CD38 (ADP-ribosyl cyclase) is a counter-receptor of CD31, an Ig superfamily member. J Immunol 1998,160: 395-402.
9. Dianzani U, Funaro A, Di Franco D, et al. Interaction between endothelium and CD4+CD45RA+ lymphocytes. Role of the human CD38 molecule. J Immunol 1994, 153: 952-9.
10. Howard M, Grimaldi JC, Bazan JF, et al. Formation and hydrolysis of cyclic ADP-ribose catalyzed by lymphocyte antigen CD38. Science 1993, 262: 1056-9.
11. Takasawa S, Tohgo A, Noguchi N, et al. Synthesis and hydrolysis of cyclic ADP-ribose by human leukocyte antigen CD38 and inhibition of the hydrolysis by ATP. J Biol Chem 1993, 268: 26052-4.
12. Summerhill RJ, Jackson DG, Galione A. Human lymphocyte antigen CD38 catalyzes the production of cyclic ADP-ribose. FEBS Lett 1993, 335: 231-3.
13. Deterre P, Gelman L, Gary-Gouy H, et al. Coordinated regulation in human T cells of nucleotide-hydrolyzing ectoenzymatic activities, including CD38 and PC-1. Possible role in the recycling of nicotinamide adenine dinucleotide metabolites. J Immunol 1996, 157: 1381-8.
14. Katz F, Povey S, Parkar M, et al. Chromosome assignment of monoclonal anti body-defined determinants on human leukemic cells. Eur J Immunol 1983, 13: 1008-13.
15. Funaro A, Horenstein AL, Calosso L, et al. Identification and characterization of an active soluble form of human CD38 in normal and pathological fluids. Int Immunol 1996, 8: 1643-50.
16. Ferrero E, Malavasi F. The metamorphosis of a molecule: from soluble enzyme to the leukocyte receptor CD38. J Leukoc Biol 1999, 65: 151-61.
17. Ferrero E, Malavasi F. Human CD38, a leukocyte receptor and ectoenzyme, is a member of a novel eukaryotic gene family of nicotinamide adenine dinucleotide+- converting enzymes: extensive structural homology with the genes for murine bone marrow stromal cell antigen 1 and Aplysian ADP-ribosyl cyclase. J Immunol 1997, 159: 3858-65.
18. Jackson DG, Bell JI. Isolation of a cDNA encoding the human CD38 (T10) molecule, a cell surface glycoprotein with an unusual discontinuous pattern of expression during lymphocyte differentiation. J Immunol 1990, 144: 2811-5.
19. Kishimoto H, Hoshino S, Ohori M, et al. Molecular mechanism of human CD38 gene expression by retinoic acid. Identification of retinoic acid response element in the first intron. J Biol Chem 1998, 273: 15429-34.
20. Malavasi F, Funaro A, Roggero S, Horenstein A, Calosso L, Mehta K. Human CD38: a glycoprotein in search of a function. Immunol Today 1994, 15: 95-7.
21. 2+ homeostasis. Nat Cell Biol 1999, 1: 409-14.
22. + glycohydrolase, ADP-ribosyl cyclase and cyclic ADP-ribose hydrolase activities at the outer surface of human erythrocytes. Biochem Biophys Res Commun 1993, 196: 1459-65.
23. Ramaschi G, Torti M, Festetics ET, Sinigaglia F, Malavasi F, Balduini C. Expression of cyclic ADP-ribose-synthetizing CD38 molecule on human platelet membrane. Blood 1996, 87: 2308-13.
24. Kramer G, Steiner G, Fodinger D, et al. High expression of a CD38-like molecule in normal prostatic epithelium and its differential loss in benign and malignant disease. J Urol 1995, 154: 1636-41.
25. Mizuguchi M, Otsuka N, Sato M. Neuronal localization of CD38 antigen in the human brain. Brain Res 1995, 697: 235-40.
26. Yamada M, Mizuguchi M, Otsuka N, Ikeda K, Takahashi H. Ultrastructural localization of CD38 immunoreactivity in rat brain. Brain Res 1997, 756: 52-60.
27. Sun L, Adebanjo OA, Moonga BS, et al. CD38/ADP-ribosyl cyclase: A new role in the regulation of osteoclastic bone resorption. J. Cell Biol. 1999, 146: 1161-72.
28. Fernandez JE, Deaglio S, Donati D, et al. Analysis of the distribution of human CD38 and of its ligand CD31 in normal tissues. J Biol Regul Homeost Agents 1998, 12: 81-91.
29. Kaisho T, Ishikawa J, Critani K, et al. BST-1, a surface molecule of bone marrow stromal cell lines that facilitates pre-β -cell growth. Proc Natl Acad Sci USA 1994, 91: 5325-9.
30. Shimaoka Y, Attrep JF, Hirano T, et al. Nurse-like cells from bone marrow and synovium of patients with rheumatoid arthritis promote survival and enhance function of human β cells. J Clin Invest 1998, 102: 606-18.
31. Okuyama Y, Ishihara K, Kimura N, et al. Human BST-1 expressed on myeloid cells functions as a receptor molecule. Biochem Biophys Res Commun 1996, 228: 838-45.
32. Kajimoto Y, Miyagawa J, Ishihara K, et al. Pancreatic islet cells express BST-1, a CD38-like surface molecule having ADP-ribosyl cyclase activity. Biochem Biophys Res Commun 1996, 219: 941-6.
33. Khoo KM, Chang CF. Characterization and localization of CD38 in the vertebrate eye. Brain Res 1999, 821: 17-25.
34. De Flora A, Guida L, Franco L, Zocchi E. The CD38/cyclic ADP-ribose system: a topological paradox. Int J Biochem Cell Biol 1997, 29: 1149-66.
35. Deaglio S, Dianzani U, Horenstein AL, et al. Human CD38 ligand. A 120-KDA protein predominantly expressed on endothelial cells. J Immunol 1996, 156: 727-34.
36. Newman PJ. Switched at birth: a new family for PECAM-1. J Clin Invest 1999, 103: 5-9.
37. Newman PJ. The biology of PECAM-1. J Clin Invest 1997, 100: S25-29.
38. Nakada MT, Amin K, Christofidou-Solomidou M, et al. Antibodies against the first Ig-like domain of human platelet endothelial cell adhesion molecule-1 (PECAM-1) that inhibit PECAM-1 -dependent homophilic adhesion block in vivo neutrophil recruitment. J Immunol 2000, 164: 452-62.
39. Morra M, Zubiaur M, Terhorst C, Sancho J, Malavasi F. CD38 is functionally dependent on the TCR/CD3 complex in human T cells. Faseb J 1998, 12: 581-92.
40. Reinis M, Morra M, Funaro A, Di Primio R, Malavasi F. Functional associations of CD38 with CD3 on the T-cell membrane. J Biol Regul Homeost Agents 1997, 11: 137-42.
41. Morra M, Deaglio S, Mallone R. CD38 cluster report. In: Kishimoto T, Goyert S, kiketani H, et al. eds. Human leukocyte differentiation antigens. Oxford: Pergamon Press. 1997, 151-4.
42. Zubiaur M, Izquierdo M, Terhorst C, Malavasi F, Sancho J. CD38 ligation results in activation of the Raf-1/mitogen-activated protein kinase and the C D3-zeta/zeta-associated protein-70 signaling pathways in Jurkat T lymphocytes. J Immunol 1997, 159: 193-205.
43. Zubiaur M, Guirado M, Terhorst C, Malavasi F, Sancho J. The CD3-gamma delta epsilon transducing module mediates CD38-induced protein-tyrosine kinase and mitogen-activated protein kinase activation in Jurkat T cells. J Biol Chem 1999, 274: 20633-42.
44. Ausiello CM, la Sala A, Ramoni C, Urbani F, Funaro A, Malavasi F. Secretion of IFN-, IL-6, granulocyte-macrophage colony-stimulating factor and IL-10 cytokines after activation of human purified T lymphocytes upon CD38 ligation. Cell. Immunol. 1996, 173: 192-7.
45. Lund FE, Yu N, Kim KM, Reth M, Howard MC. Signaling through CD38 augments β cell antigen receptor (BCR) responses and is dependent on BCR expression. J Immunol 1996, 157: 1455-67.
46. Funaro A, Morra M, Calosso L, Zini MG, Ausiello CM, Malavasi F. Role of the human CD38 molecule in β cell activation and proliferation. Tissue Antigens 1997, 49: 7-15.
47. Kumagai M, Coustan-Smith E, Murray DJ, et al. Ligation of CD38 suppresses human B lymphopoiesis. J Exp Med 1995, 181: 1101-10.
48. Kitanaka A, Ito C, Nishigaki H, Campana D. CD38-mediated growth suppression of β-cell progenitors requires activation of phosphatidylinositol 3-kinase and involves its association with the protein product of the c-cbl proto-oncogene. Blood 1996, 88: 590-8.
49. Zupo S, Rugari E, Dono M, Taborelli G, Malavasi F, Ferrarini M. CD38 signaling by agonistic monoclonal antibody prevents apoptosis of human germinal center β cells. Eur J Immunol 1994, 24: 1218-22.
50. Damle RN, Wasil T, Fais F, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999, 94: 1840-7.
51. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999, 94: 1848-54.
52. Ishikawa H, Kawano MM. Biological significance of heterogeneity in human myeloma cells. Int J Hematol 1998, 68: 363-70.
53. Koehler M, Behm F, Hancock M, Pui CH. Expression of activation antigens CD38 and CD71 is not clinically important in childhood acute lymphoblastic leukemia. Leukemia 1993, 7: 41-5.
54. Yamamoto H, Uchigata Y, Okamoto H. Streptozotocin and alloxan induce DNA strand breaks and poly(ADP-ribose) synthetase in pancreatic islets. Nature 1981, 294: 284-6.
55. Yamamoto H, Uchigata Y, Okamoto H. DNA strand breaks in pancreatic islets by in vivo administration of alloxan or streptozotocin. Biochem Biophys Res Commun 1981, 103: 1014-20.
56. Okamoto H. Regulation of proinsulin synthesis in pancreatic islets and a new aspect to insulin-dependent diabetes. Mol Cell Biochem 1981, 37: 43-61.
57. Uchigata Y, Yamamoto H, Kawamura A, Okamoto H. Protection by superoxide dismutase, catalase, and poly(ADP-ribose) synthetase inhibitors against alloxan- and streptozotocin-induced islet DNA strand breaks and against the inhibition of proinsulin synthesis. J Biol Chem 1982, 257: 6084-8.
58. Uchigata Y, Yamamoto H, Nagai H, Okamoto H. Effect of poly(ADP-ribose) synthetase inhibitor administration to rats before and after injection of alloxan and streptozotocin on islet proinsulin synthesis. Diabetes 1983, 32: 316-8.
59. Takamura T, Kato I, Kimura N, et al. Transgenic mice over-expressing Type 2 nitric oxide synthase in pancreatic β cells develop insulin-dependent diabetes without insulitis. J Biol Chem 1998, 273: 2493-6.
60. + depletion in Type I diabetes. Nature Mad 1999, 5: 269-70.
61. Pieper AA, Brat DJ, Krug DK, et al. Poly(ADP-ribose) polymerase-deficient mice are protected from streptozotocin-induced diabetes. PNAS 1999, 96: 3059-64.
62. Okamoto H, Yamamoto H, Takasawa S, et al. Molecular mechanism of degeneration, oncogenesis and regeneration of pancreatic β-cells of islets of Langerhans. In: Shafrir E, Renold AE eds. Lessons from animal diabetes II. London: John Libbey & Company Ltd. 1988, 149-57.
63. Okamoto H. The molecular basis of experimental diabetes. In: Okamoto H ed. Molecular biology of the islets of Langerhans. Cambridge: Cambridge University Press. 1990, 209-31.
64. Takasawa S, Okamoto H. Pancreatic β-cell death, regeneration and insulin secretion: roles of poly(ADP-ribose) polymerase and cyclic ADP-ribose. Int J Exp Diabetes Res 2002, 3: 79-96.
65. Takasawa S, Okamoto H. The CD38-cyclic ADP-ribose signal system in pancreatic β-cells. The discovery and biological significance of a novel signal system in mammalian cells. In:. Lee HC ed. Cyclic ADP-Ribose and NAADP: Structure, Metabolism and Physiological Functions. Dordrecht: Kluwer, 2002. Chapter 14.
66. Germain M, Scovassi I, Poirier GG. Role of poly(ADP-ribose) polymerase in apoptosis. In: Szabó C ed. Cell Death - The Role of Poly(ADP-ribose) polymerase -. Boca Raton: CRC Press. 2000, 209-25.
67. Sauter B, Albert ML, Francisco L, Larsson M, Somersan S, Bhardwaj N. Consequences of cell death: Exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells. J Exp Med 2000, 191: 423-33.
68. Cocco RE, Ucker DS. Distinct modes of macrophage re-cognition for apoptotic and necrotic cells are not specified exclusively by phosphatidylserine exposure. Mol Biol Cell 2001, 12: 919-30.
69. Ashcroft FM, Harrison DE, Ashcroft SJH. Glucose induced closure of single potassium channels in isolated rat pancreatic β -cells. Nature 1984, 312: 446-8.
70. Takasawa S, Nata K, Yonekura H, Okamoto H. Cyclic ADP-ribose in insulin secretion from pancreatic β-cells. Science 1993, 259: 370-3.
71. 2+ mobilization in normal and diabetic β -cells. J Biol Chem 1998, 273: 2497-500.
72. An NH, Han MK, Um C, et al. Significance of ecto-cyclase activity of CD38 in insulin secretion of mouse pancreatic islet cells. Biochem Biophys Res Commun 2001, 282: 781-6.
73. Koguma T, Takasawa S, Tohgo A, et al. Cloning and characterization of cDNA encoding rat ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase (homologue to human CD38) from islets of Langerhans. Biochim Biophys Acta 1994, 1223: 160-2.
74. Tohgo A, Munakata H, Takasawa S, et al. Lysine 129 of CD38 (ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase) participates in the binding of ATP to inhibit the cyclic ADP-ribose hydrolase. J Biol Chem 1997, 272: 3879-82.
75. 2+ store in neuroendocrine cells with a vesicle-associated membrane protein aequorin chimaera. J Cell Biol 2001, 155: 41-51.
76. 2+ from islet microsomes. J Biol Chem 1997, 272: 3133-6.
77. Pirsch JD, Miller J, Deierhoi MH, Vincenti F, Filo RS. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation: FK506 Kidney Transplant Study Group. Transplantation 1997, 63: 977-83.
78. 2+ mobilization. J Biol Chem 1995, 270: 30257-9.
79. Kato I, Takasawa S, Akabane A, et al. Regulatory role of CD38 (ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase) in insulin secretion by glucose in pancreatic β-cells: Enhanced insulin secretion in CD38 transgenic mice. J Biol Chem 1995, 270: 30045-50.
80. i and insulin secretion. J Biol Chem 1999, 274: 1869-72.
81. Ikehata F, Satoh J, Nata K, et al. Autoantibodies against CD38 (ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase) which impair glucose-induced insulin secretion in non-insulin dependent diabetes patients. J Clin Invest 1998, 102: 395-401.
82. Pupilli C, Giannini S, Marchetti P. Autoanitibodies to CD38 (ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase) in Caucasian patients with diabetes: Effects on insulin release from human islets. Diabetes 1999, 48: 2309-15.
83. Mallone R, Ortolan E, Baj G. Autoantibody response to CD38 in Caucasian patients with Type 1 and Type 2 diabetes: immunological and genetic characterization. Diabetes 2001, 50: 752-62.
84. Antonelli A, Tuomi T, Nannipieri M, et al. Autoimmunity to CD38 and GAD in Type II and Type I diabetes: CD38 and HLA genotypes and clinical phenotypes. Diabetologia 2002, 45: 1298-306.
85. Mallone R, Ortolan E, Pinach S, et al. Anti-CD38 autoantibodies: Characterisation in new-onset Type I diabetes and latent autoimmune diabetes of the adult (LADA) and comparison with other islet autoantibodies. Diabetologia 2002, 45: 1667-77.
86. Antonelli A, Baj G, Marchetti P, et al. Human anti-CD38 autoantibodies raise intracellular calcium and stimulate insulin release in human pancreatic islets. Diabetes 2001, 50: 985-91.
87. Marchetti P, Antonelli A, Lupi R, et al. Prolonged in-vitro exposure to anti-CD38 autoantibodies impairs the function and survival of human pancreatic islets. Diabetes 2002, 51: S474-7.
88. Yagui K, Shimada F, Mimura M, et al. A missense mutation in the CD38 gene, a novel factor for insulin secretion: association with Type II diabetes mellitus in Japanese subjects and evidence of abnormal function when expressed in vitro. Diabetologia 1998, 41: 1024-8.
89. Ferrero E, Saccucci F, Malavasi F. The human CD38 gene: polymorphism, CpG island, and linkage to the CD157 (BST-1) gene. Immunogenetics 1999, 49: 597-604.
90. Antonelli A, Fallahi P, Nesti C, et al. Anti-CD38 autoimmunity in patients with chronic autoimmune thyroiditis or Graves' disease. Clin Exp Immunol 2001, 126: 426-31.